Dr. Mulroney is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
3855 Health Sciences Drive
#0960
San Diego, CA 92093Phone+1 858-822-6600Fax+1 858-822-6844- Is this information wrong?
Education & Training
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 1990 - 1992
University of WashingtonFellowship, Hematology and Medical Oncology, 1989 - 1990
Duke University HospitalResidency, Internal Medicine, 1986 - 1990
Johns Hopkins University School of MedicineClass of 1986
University of PennsylvaniaBA, Biochemistry, 1978 - 1982
Certifications & Licensure
CA State Medical License 1990 - 2025
WA State Medical License 1989 - 1990
NC State Medical License 1989 - 1990- American Board of Internal Medicine Hematology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Ibrutinib and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma Start of enrollment: 2016 Jun 20
Publications & Presentations
PubMed
- 1 citationsExtracorporeal photopheresis for the treatment of chronic graft versus host disease.Emin Kansu, David Ward, Amber P Sanchez, Robyn Cunard, Mutlu Hayran, Beril Huseyin, Majella Vaughan, Grace Ku, Peter Curtin, Carolyn Mulroney, Caitlin Costello, Januar...> ;Hematology. 2022 Dec 1
- 2 citationsCase Report: Multiple Chromosomal Translocations Including Novel CIITA-CREBBP Fusion and Mutations in a Follicular Lymphoma.Huan You Wang, Ethan Sokol, Aaron M. Goodman, Andrew L. Feldman, Carolyn Mulroney> ;Frontiers in Oncology. 2021 Mar 10
- Comprehensive Genomic Profiling Reveals Diverse but Actionable Molecular Portfolios across Hematologic Malignancies: Implications for Next Generation Clinical Trials.Galanina, N.,Bejar, R.,Choi, M.,Goodman, A.,Wieduwilt, M.,Mulroney, C.,Kim, L.,Yeerna, H.,Tamayo, P.,Vergilio, J. A.,Mughal, T. I.,Miller, V.,Jamieson, C.,Kurzrock, R.> ;Cancers (Basel). 2018 Dec 26
- Join now to see all
Abstracts/Posters
- Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Sa...Carolyn Mulroney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone As Salvage Therapy in Relapsed/Refractory Multiple Myeloma: Results of a Sa...Carolyn Mulroney, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Professional Memberships
- Member
- Member
- American Society of Blood and Marrow Transplantation ( ASBMT)Member
Hospital Affiliations
UC San Diego Medical Center - HillcrestSan Diego, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
